Strain-Independent Therapeutic Antibodies for Influenza

流感病毒毒株无关的治疗性抗体

基本信息

批准号：
8780477
负责人：
Lawrence Michael Kauvar
金额：
$ 29.87万
依托单位：
TRELLIS BIOSCIENCE, INC.
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-07-01 至 2015-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8780477
关键词：
Acute Advanced Development Affect Affinity Animals Antibodies Antigens Antiviral Agents Arts Binding Biodistribution Biological Birds Cell Line Cells Clinical Clinical Trials Communicable Diseases Cytomegalovirus Disease Dose Drug Formulations Epitopes Event Family suidae Ferrets Genetic Recombination Half-Life Hemagglutinin Human Immunity Immunohistochemistry In Vitro Infection Influenza Influenza A Virus, H1N1 Subtype Lung Marketing Mediating Modeling Monoclonal Antibodies Mus Pathology Phase Population Pre-Clinical Model Production Prophylactic treatment Proteins Publishing Respiratory syncytial virus Route Sentinel Serum Site Specificity Staging T-Lymphocyte Technology Testing Therapeutic Therapeutic Agents Therapeutic antibodies Toxic effect Toxicity Tests Toxicology Transfection Virus Work base biosafety level 3 facility cell bank cost design human disease human monoclonal antibodies human tissue immunogenic improved in vitro activity in vivo influenzavirus innovation method development monoclonal antibody production mouse model novel therapeutics pandemic disease pathogen programs public health relevance screening seasonal influenza

项目摘要

DESCRIPTION (provided by applicant): Trellis Bioscience's CellSpot" technology for identification of rare human antibodies with high specificity and affinity against multiple antigen has enabled discovery of highly efficacious strain- independent antibodies to Respiratory Syncytial Virus and to Cytomegalovirus. We have now applied CellSpot to isolate two native human antibodies with broad reactivity to Group 1 and Group 2 influenza A strains respectively. Both of these antibodies have now been shown to have in vivo efficacy. In addition, we have isolated a human antibody with in vitro activity against Influenza B. We propose to advance these therapeutic candidates to IND stage, including additional neutralization studies in vitro and in vivo, manufacturing, toxicity, and PK studies. The resulting clinical candidates are expected to provide potent post-infection antiviral activity against all currently circulating strains, and effective prophylaxis against any emerging pandemic strain.

描述（由申请人提供）：Trellis Bioscience 的“CellSpot”技术用于鉴定对多种抗原具有高特异性和亲和力的稀有人类抗体，使得能够发现针对呼吸道合胞病毒和巨细胞病毒的高效毒株独立抗体。我们现在已将 CellSpot 应用于分离出两种分别对 1 组和 2 组甲型流感病毒株具有广泛反应性的天然人抗体，这两种抗体现已被证明具有体内功效。一种具有体外抗 B 型流感活性的人类抗体。我们建议将这些治疗候选药物推进到 IND 阶段，包括额外的体外中和研究和体内、生产、毒性和药代动力学研究。由此产生的临床候选药物预计将针对所有当前流行的病毒株提供有效的感染后抗病毒活性，并对任何新出现的大流行病毒株提供有效的预防。